Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | VSIR | Q9H7M9 | 1/20 | 0.43 |
| ▸ | JAK2 | O60674 | 1/20 | 0.42 |
| ▸ | VCP | P55072 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.41 |
| ▸ | ABCB1 | P08183 | 3/20 | 0.41 |
| ▸ | ABCC1 | P33527 | 3/20 | 0.41 |
| ▸ | ABCG2 | Q9UNQ0 | 3/20 | 0.41 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.41 |
| ▸ | ABCC3 | O15438 | 1/20 | 0.41 |
| ▸ | ESR1 | P03372 | 1/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | PGR | P06401 | 1/20 | 0.41 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.41 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13086645 | 0.85 | PDE4B (0.45) | VSIRJAK2MEN1KMT2ACYP2C9 | |
| SCHEMBL13547970 | 0.82 | VSIR (0.51) | VSIRALDH1A1MAPTHTT | |
| SCHEMBL249084 | 0.82 | SYK (0.49) | JAK2VCPCYP2C9CYP2C19ABCB1 | |
| SCHEMBL14369686 | 0.78 | CYP2C9 (0.55) | VSIRJAK2MEN1KMT2ACYP2C9 | |
| SCHEMBL13729350 | 0.75 | JAK2 (0.56) | JAK2VCPCYP2C9CYP2C19ABCB1 | |
| SCHEMBL13086839 | 0.73 | CYP2C19 (0.48) | JAK2CYP2C9CYP2C19ABCB1ABCC1 | |
| SCHEMBL14369689 | 0.73 | SYK (0.39) | MEN1KMT2ACYP2C9CYP2C19ABCB1 | |
| SCHEMBL13086783 | 0.73 | CYP2C19 (0.67) | JAK2MEN1KMT2ACYP2C9CYP2C19 | |
| SCHEMBL21914834 | 0.72 | CTSK (0.58) | JAK2MEN1KMT2ACYP2C9CYP2C19 | |
| SCHEMBL6861898 | 0.70 | EGLN2 (0.45) | MEN1KMT2ACYP2C9CYP2C19ABCB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2781510-B1 | HIV INHIBITING 5,6-SUBSTITUTED PYRIMIDINES | JANSSEN SCIENCES IRELAND UC (IE) | 2016-12-14 | — | — | EP | disclosed |
| US-9006243-B2 | HIV inhibiting 6-substituted pyrimidines | JANSSEN R&D IRELAND (IE) | 2015-04-14 | — | — | US | disclosed |
| US-9006243-B2 | HIV inhibiting 6-substituted pyrimidines | JANSSEN R&D IRELAND (IE) | 2015-04-14 | — | — | US | disclosed |
| EP-2781510-A1 | HIV inhibiting 5,6-substituted pyrimidines | Janssen R&D Ireland (IE) | 2014-09-24 | — | — | EP | disclosed |
| EP-2114902-B1 | HIV INHIBITING 5,6-SUBSTITUTED PYRIMIDINES | JANSSEN R & D IRELAND (IE) | 2014-09-17 | — | — | EP | disclosed |
| US-8318736-B2 | HIV inhibiting 5,6-substituted pyrimidines | JANSSEN R&D IRELAND (IE) | 2012-11-27 | — | — | US | disclosed |
| US-8318736-B2 | HIV inhibiting 5,6-substituted pyrimidines | JANSSEN R&D IRELAND (IE) | 2012-11-27 | — | — | US | disclosed |
| US-20100261722-A1 | HIV INHIBITING 5, 6-SUBSTITUTED PYRIMIDINES | TIBOTEC PHARMACEUTICALS LTD. | 2010-10-14 | — | — | US | disclosed |
| US-20100261722-A1 | HIV INHIBITING 5, 6-SUBSTITUTED PYRIMIDINES | TIBOTEC PHARMACEUTICALS LTD. | 2010-10-14 | — | — | US | disclosed |
| US-20100016317-A1 | HIV INHIBITING 6-SUBSTITUTED PYRIMIDINES | JANSSEN SCIENCES IRELAND UC (IE) | 2010-01-21 | — | — | US | disclosed |
| US-20100016317-A1 | HIV INHIBITING 6-SUBSTITUTED PYRIMIDINES | JANSSEN SCIENCES IRELAND UC (IE) | 2010-01-21 | — | — | US | disclosed |
| WO-2008080964-A1 | HIV INHIBITING 6-SUBSTITUTED PYRIMIDINES | TIBOTEC PHARMACEUTICALS LTD. (IE) | 2008-07-10 | — | — | WO | disclosed |
| WO-2008080965-A2 | HIV INHIBITING 5,6-SUBSTITUTED PYRIMIDINES | TIBOTEC PHARMACEUTICALS LTD. (IE) | 2008-07-10 | — | — | WO | disclosed |
| US-7276510-B2 | HIV replication inhibitors | JANSSEN PHARMACEUTICA, INC. (BE) | 2007-10-02 | — | — | US | disclosed |
| US-7276510-B2 | HIV replication inhibitors | JANSSEN PHARMACEUTICA, INC. (BE) | 2007-10-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100261722-A1 | HIV INHIBITING 5, 6-SUBSTITUTED PYRIMIDINES | NR0B1, NR1H3, CCR10 | VSIR 2558/4885JAK2 3944/4885VCP 3784/4885 |
| US-20100016317-A1 | HIV INHIBITING 6-SUBSTITUTED PYRIMIDINES | CCR5, CTR9, NR1H3 | VSIR 2212/4885JAK2 3663/4885VCP 4080/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.